Drugs Made In America Acquisition Rights (DMAAR) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 93 222 sessions, November 4, 2025 to November 4, 2026
- Largest daily move
- +54.5% close of July 21, 2026
- 1-year change
- -38.8% closing prices, November 4, 2025 to November 4, 2026
- 1-month change
- -13.6% closing prices, October 2, 2026 to November 4, 2026
Company Description
Drugs Made In America Acquisition Rights (NASDAQ: DMAAR) is classified in the blank checks industry.
DMAAR has declined 38.8% over the past year. The last closing price was $0.1101.
For FY2025, Drugs Made In America Acquisition Rights reported net income of $5.9M.
This page collects what Stock Titan holds for DMAAR, including price data, SEC filings, financial highlights, and short interest trends.
Stock Performance
Drugs Made In America Acquisition Rights (DMAAR) closed at $0.1101 on November 4, 2026. Over the past 12 months, the price has lost 38.8%.
DMAAR Metrics & Rankings
Price returns through November 4, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
SEC Filings
Drugs Made In America Acquisition Rights has filed 10 recent SEC filings, including 4 Form SCHEDULE 13G/A, 3 Form 8-K, 2 Form 10-Q, 1 Form SCHEDULE 13G. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMAAR SEC filings →
Financial Highlights
Drugs Made In America Acquisition Rights reported operating income of -$2.8M in FY2025, and net income was $5.9M. The company generated -$539K in operating cash flow. The current ratio was 0.03, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Drugs Made In America Acquisition Rights (DMAAR) currently stands at 57.4 thousand shares, down 6.0% from the previous reporting period. Since November 2025, short interest has increased by 165.0%.
Days to Cover History
Days to cover for Drugs Made In America Acquisition Rights (DMAAR) currently stands at 7.2 days, up 31% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 54%. Across the settlements charted above, it has ranged from 1.0 to 7.2 days.
DMAAR Company Profile & Sector Positioning
Drugs Made In America Acquisition Rights (DMAAR) and is listed on the NASDAQ.